Investment breakthrough for BrainRepair UG start-up - Stem cell treatment for newborns / Dr. Metin Colpan, founder of Nasdaq listed Qiagen N.V. acquired 5% of BrainRepair UG shares worth EUR 15M (FOTO)

Bochum (ots) - One of the most successful inventors and entrepreneurs who
masterminded the unprecedented success of Qiagen N.V. from a start-up to a 10
billion market cap enterprise has taken the decision to refocus his activities
on BrainRepair UG, a spin-off of the Ruhr-University Bochum (RUB). BrainRepair
UG has developed a unique method based on own (autologous) cord blood stem cells
to treat brain damage and cerebral palsy (CP) in newborns affecting 70,000
babies in the EU each year. Metin Colpan's patented invention has become a
standard method recommended by the World Health Organization (WHO) and is used
by researchers all over the world, changing the way they can access, purify and
understand genetic data in DNA and RNA. The European Patent Office states
"...The tireless work of German scientist Metin Colpan over four decades has
paved the way for rapid and effective genetic data analysis, enabling
researchers to better detect disease and unlocking new therapies for conditions,
including COVID-19," and Prof. Dr. Arne Jensen, Co-Founder and CEO of
BrainRepair UG, continues "We are delighted that we now can draw on the vast
experience Dr. Colpan is offering us as Member of the Board of Directors and
Chairman of the Advisory Board on our way to the stock market at Nasdaq First
North for which the IPO is planned in November 2021." BrainRepair UG's stem cell
product has been granted the worldwide first 'Orphan Drug Designation' (ODD) by
the European Commission and the European Medicines Agency. This designation
guarantees market exclusivity in all EU member states for 12 years upon market
authorisation. Prof. Arne Jensen stresses, "All our personal, scientific,
clinical, and philanthropic efforts serve the ultimate goal - to combat
infantile Cerebral palsy, the most common disability in childhood, and stop CP
in children!"

About Qiagen N.V.

QIAGEN is a German provider of sample and assay technologies for molecular
diagnostics, applied testing, academic and pharmaceutical research. Consolidated
under the Dutch holding QIAGEN N.V. , the company operates more than 35 offices
in over 25 countries.[16] QIAGEN's shares are listed at the NYSE (using ticker
QGEN) and at the Frankfurt Stock Exchange in the Prime Standard (using ticker
QIA). Thierry Bernard is the company's Chief Executive Officer. The main
operative headquarters are located in Hilden, Germany. Number of employees:
about 5,000. Total equity: US $2,634.970 million. Industry: Biotechnology. Total
assets: US $5,748.332 million. Market capitalization: US $ 11,123 billion.

About BrainRepair UG

BrainRepair UG is a clinical stage start-up developing cutting edge stem cell
treatments based on human cord blood for a wide range of indications related to
brain injury in children including those caused by oxygen lack and inflammation
(PVL, HIE, NE), hemorrhage, stroke, cerebral palsy (CP), traumatic brain injury
(TBI), and spinal cord injury (SCI). BrainRepair UG is the first Biotech company
worldwide whose stem cell products have been awarded 'Orphan Medicinal Product
Designations' for the treatment of brain injury in newborn infants (PVL, NE) by
the European Commission and the European Medicines Agency, EMA. BrainRepair's
Headquarter is in Bochum, Germany. You may visit the website at
https://brainrepair.eu/ for more information.

Links:

Metin Colpan (DE) - Finalist for the European Inventor Award 2021 - EPO
https://www.epo.org/news-events/events/european-inventor/finalists/2021/colpan.h
tml

Autologous Cord Blood Therapy for Infantile Cerebral Palsy: From Bench to
Bedside,Obstet Gynecol Int vol.2014,12p;
https://www.hindawi.com/journals/ogi/2014/976321/

First Autologous Cord Blood Therapy for Pediatric Ischemic Stroke and Cerebral
Palsy Caused byCephalic Molding during Birth: Individual Treatment with
Mononuclear Cells", Case Reports in Transplantation, vol. 2016, Article ID
1717426, 9 pages, 2016.
https://www.hindawi.com/journals/crit/2016/1717426/

EMA Orphan medicinal Product Designation Periventricular leukomalacia (PVL):
https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3161744

EMA Orphan medicinal Product Designation Newborn encephalopathy (NE):
https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3161743

Contact:

BrainRepair UG (haftungsbeschränkt) Prof. Dr. med. Arne Jensen, MD, MBA
Ruhr-University Bochum Campus Clinic Gynaecology
Universitätsstr. 136 44799 Bochum, Germany
Tel.: [phone]
Fax.: [phone]
Email: mailto:[e-mail]

Additional content: http://presseportal.de/pm/148654/4925646
OTS: BrainRepair UG